5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.69▼ | 1.72▼ | 1.73▼ | 1.78▼ | 1.93▼ |
MA10 | 1.71▼ | 1.75▼ | 1.77▼ | 1.86▼ | 1.98▼ |
MA20 | 1.75▼ | 1.78▼ | 1.79▼ | 2.06▼ | 2.37▼ |
MA50 | 1.79▼ | 1.79▼ | 1.85▼ | 2.33▼ | 4.03▼ |
MA100 | 1.80▼ | 1.88▼ | 2.00▼ | 2.62▼ | 11.54▼ |
MA200 | 1.89▼ | 2.04▼ | 2.37▼ | 3.75▼ | 65.45▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.007▼ | -0.012▼ | -0.010▼ | -0.033▼ | 0.090▲ |
RSI | 24.261▼ | 26.135▼ | 30.336▼ | 42.474▼ | 37.171▼ |
STOCH | 5.506▼ | 4.742▼ | 6.030▼ | 9.164▼ | 6.418▼ |
WILL %R | -95.000▼ | -96.875▼ | -97.436▼ | -96.875▼ | -97.942▼ |
CCI | -125.109▼ | -187.469▼ | -203.377▼ | -105.181▼ | -89.040 |
Tuesday, February 04, 2025 06:01 AM
Marlborough, Massachusetts--(Newsfile Corp. - January 15, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL ...
|
Monday, February 03, 2025 05:45 AM
Registration Link for Presentation and live Q&A to take place, Tuesday February 4, 2025 at 2:00 pm ESTMarlborough, Massachusetts--(Newsfile ...
|
Monday, February 03, 2025 04:47 AM
About Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company advancing its proprietary INTASYL siRNA gene silencing technology to eliminate ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
18/02/25 | 1.77 | 1.8399 | 1.67 | 1.70 | 305,822 |
14/02/25 | 1.83 | 1.88 | 1.79 | 1.81 | 257,846 |
13/02/25 | 1.80 | 1.859 | 1.76 | 1.79 | 170,273 |
12/02/25 | 1.91 | 1.91 | 1.765 | 1.83 | 172,557 |
11/02/25 | 1.78 | 1.84 | 1.745 | 1.78 | 219,553 |
10/02/25 | 1.92 | 1.92 | 1.78 | 1.78 | 420,329 |
07/02/25 | 2.06 | 2.06 | 1.88 | 1.89 | 456,722 |
06/02/25 | 2.05 | 2.0738 | 1.9897 | 2.03 | 197,719 |
05/02/25 | 2.01 | 2.05 | 1.93 | 1.99 | 439,606 |
04/02/25 | 2.11 | 2.175 | 2.02 | 2.04 | 484,512 |
|
|
||||
|
|
||||
|
|